Robbins LLP Reminds Regencell Bioscience Investors of Ongoing Securities Class Action Litigation

NEW YORK, June 2026 – Shareholders of Regencell Bioscience Holdings Limited (NASDAQ: RGC) are being reminded of an ongoing securities class action lawsuit that seeks to represent investors who allegedly suffered financial losses after purchasing the company’s securities during a specified class period. Robbins LLP has encouraged eligible investors to review their legal rights and consider participating in the litigation as the case progresses.

Background of the Lawsuit Against Regencell Bioscience

The securities class action was filed on behalf of investors who purchased or otherwise acquired Regencell Bioscience securities during the period between October 28, 2024, and October 31, 2025. The lawsuit alleges that the company and certain executives may have made materially false or misleading statements regarding the company’s business operations, market conditions, and risk exposure.

According to the allegations outlined in the complaint, investors were allegedly not fully informed about factors that could have significantly affected the company's stock performance and overall market valuation. The complaint claims that these omissions and misrepresentations may have resulted in investors purchasing securities at artificially inflated prices.

Key Allegations Raised by Investors

The lawsuit centers on several major allegations concerning Regencell’s public disclosures and investor communications. Plaintiffs claim that the company failed to adequately disclose information regarding:

• The company’s alleged vulnerability to market manipulation.
• Potential risks associated with unusual trading activity involving its shares.
• Exposure to heightened regulatory scrutiny and possible government investigations.
• Potential legal, financial, and reputational consequences arising from those risks.
• The overall impact of these issues on the company’s future business prospects.

Investors contend that had this information been properly disclosed, the market may have valued the company differently, potentially preventing significant losses experienced by shareholders.

Department of Justice Investigation Triggered Market Reaction

A major development cited in the lawsuit occurred on October 31, 2025, when Regencell disclosed that it had received correspondence and a subpoena from the U.S. Department of Justice (DOJ). The disclosure indicated that federal authorities were conducting an investigation related to trading activity involving the company’s ordinary shares.

Following the announcement, Regencell’s stock price experienced a significant decline. Market participants reacted negatively to the news, with investors expressing concerns about potential regulatory findings and the broader implications of the investigation.

The lawsuit alleges that this disclosure revealed information that should have been communicated to investors earlier, contributing to substantial losses for shareholders when the stock price fell.

Investor Losses and Class Action Claims

The class action seeks to recover damages for investors who sustained financial losses after purchasing Regencell securities during the alleged class period. Plaintiffs argue that the market price of the company's shares was artificially inflated due to incomplete or misleading information made available to investors.

If the court determines that securities laws were violated, eligible investors could potentially receive compensation through a settlement or court judgment. However, no determination of liability has been made, and the allegations remain subject to judicial review.

Understanding the Role of a Lead Plaintiff

As part of the class action process, investors may seek appointment as a Lead Plaintiff. A Lead Plaintiff serves as the representative of the proposed class and helps oversee litigation decisions on behalf of all affected shareholders.

The Lead Plaintiff typically works closely with legal counsel, reviews significant developments in the case, and helps ensure that the interests of class members are represented throughout the litigation process.

Legal experts note that investors do not need to serve as Lead Plaintiff in order to remain eligible for any future recovery that may result from the lawsuit.

Robbins LLP Encourages Investors to Review Their Legal Options

Robbins LLP has encouraged investors who suffered losses associated with Regencell securities to evaluate their legal rights and determine whether participation in the class action may be appropriate for their circumstances.

The law firm emphasizes that investors should carefully review relevant trading records, account statements, and documentation that may support claims related to losses incurred during the class period.

By remaining informed about developments in the litigation, investors can better understand available options and important deadlines associated with the case.

Broader Implications for Public Companies

The Regencell litigation highlights the importance of transparency and accurate disclosure within public markets. Securities regulations require publicly traded companies to provide investors with material information that may influence investment decisions.

When questions arise regarding the completeness or accuracy of corporate disclosures, securities class actions often become an important mechanism through which investors seek accountability and financial recovery.

Market observers note that cases involving regulatory investigations, trading activity concerns, and disclosure practices continue to attract significant attention from shareholders, regulators, and legal professionals.

What Investors Should Watch Moving Forward

As the litigation proceeds, several developments may influence the outcome of the case, including:

• Court rulings regarding the sufficiency of the complaint.
• Appointment of Lead Plaintiff representatives.
• Potential motions filed by defendants.
• Discovery and evidence-gathering procedures.
• Possible settlement discussions.
• Updates related to any regulatory investigations.

Investors and market participants are expected to monitor these developments closely, as they could affect both the litigation timeline and potential recovery opportunities.

Conclusion

The pending securities class action involving Regencell Bioscience Holdings Limited represents a significant legal matter for investors who purchased company shares during the alleged class period. The lawsuit focuses on claims that shareholders were not provided with complete and accurate information regarding market risks, regulatory concerns, and trading-related issues.

While the allegations have not yet been proven in court, Robbins LLP continues to remind affected investors of their rights and the importance of staying informed as the litigation advances. The outcome of the case could have meaningful implications for both shareholders and broader discussions surrounding corporate disclosure practices and investor protection.

#RegencellBioscience #RGCStock #ClassActionLawsuit #InvestorRights #SlimScan #GrowthStocks #CANSLIM